Examples
Worked examples
- Is an instance
A sponsor preparing an original IND for a small-molecule drug candidate assembles a CMC package describing the drug substance's chemical structure and synthesis route, the drug product's formulation and manufacturing process, the analytical methods and specifications used to release each batch, and preliminary stability data supporting the proposed clinical-supply shelf life -- filed as Module 3 of the eCTD alongside the nonclinical (Module 4) and clinical protocol (Module 5) sections.
- Is an instance
As a biologic moves from Phase 1 through Phase 3, its CMC section is expected to mature substantially: cell-line and manufacturing-process characterization deepens, in-process and release specifications tighten as more batch data accumulates, and process-validation data (see FDA Process Validation) is added ahead of a BLA -- FDA's tiered CMC expectations mean a Phase 1 CMC package that would have been acceptable to initiate first-in-human dosing is routinely insufficient to support marketing approval without substantial additional characterization and validation work.
Counter-examples
Looks similar, but isn't
- Not an instance
A well-documented clinical protocol amendment, or a complete set of nonclinical toxicology study reports, is not CMC information on its own -- CMC specifically concerns the chemistry, manufacturing process, and quality controls of the drug substance and drug product themselves, not the clinical or nonclinical evidence for how the product behaves once administered.
Editorial commentary
Chemistry, Manufacturing, and Controls (CMC) is the standard shorthand for the body of data describing what a drug substance or drug product is and how it is consistently made and controlled to meet that description — as distinct from the nonclinical data describing how it behaves in animals or the clinical data describing how it behaves in people. In an eCTD-formatted regulatory submission, CMC information is filed as Module 3 (Quality); “CMC” is the term the drug-development community uses in practice for that module’s content, not a formally defined ICH term in its own right.
What CMC data must show
Regardless of a product’s development stage, a CMC package is built to answer the same core questions, at a depth appropriate to that stage:
- Identity — what the drug substance and drug product actually are: chemical structure and synthesis route for a small molecule, or expression system, cell line, and molecular characterization for a biologic.
- Strength — confirmation that each batch contains the labeled amount of active ingredient.
- Quality and purity — specifications (analytical test methods paired with acceptance criteria) applied at critical points in manufacturing and at batch release, covering impurities, degradation products, and other quality attributes.
- Manufacturing process — a description of the process used to produce the drug substance and drug product, including in-process controls, at a level of detail sufficient for a regulator to assess consistency and control.
- Stability — data supporting the proposed container closure system and shelf life under defined storage conditions.
These expectations are not static across a product’s lifecycle. FDA and other ICH-aligned regulators apply a tiered, risk-based standard: a CMC package sufficient to support first-in-human dosing under an Investigational New Drug (IND) application is deliberately less exhaustive than the CMC package required to support a marketing application, where manufacturing-process validation and continued process verification (CPV), tightened specifications based on accumulated batch history, and more extensive characterization are expected.
Where CMC sits in a regulatory submission
In an eCTD-formatted application to FDA — an IND, NDA, ANDA, or BLA — CMC information is filed as Module 3, organized by the ICH Common Technical Document (CTD) structure into drug-substance and drug-product sections covering manufacture, characterization, control, and stability. Module 2 includes a Quality Overall Summary that synthesizes the Module 3 data for reviewers. Because Module 3 sits alongside Module 4 (nonclinical study reports) and Module 5 (clinical study reports) in the same submission, “CMC” is often used loosely to mean “the Module 3 section” even though, strictly, CMC describes the subject matter rather than the module number itself.
Manufacturing controls: process validation and GMP
The “controls” component of CMC is where a product’s manufacturing quality system connects most directly to two related but distinct regulatory frameworks. FDA Process Validation is the CGMP lifecycle approach (process design, process qualification, and continued process verification) used to demonstrate that a manufacturing process reliably produces product meeting its specifications; validation data and the supporting rationale for a process’s control strategy are core CMC content, particularly ahead of a marketing application. For active pharmaceutical ingredient manufacturing specifically, ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is the harmonized GMP standard that CMC quality sections for API manufacture are typically written to demonstrate compliance with.
Why CMC deficiencies matter
An incomplete or unconvincing CMC package is one of the most common substantive grounds for regulatory delay. FDA can place a clinical hold on an IND, or issue a Complete Response Letter (CRL) on a marketing application, specifically because the CMC data submitted does not adequately establish identity, strength, quality, purity, or manufacturing consistency — independent of whether the nonclinical and clinical data packages are sound. Research administrators and regulatory-affairs staff coordinating a submission timeline should treat CMC readiness as a distinct workstream from clinical and nonclinical readiness, since it depends on manufacturing and analytical development timelines that often run on a different critical path than clinical-trial execution.
Related CASRAI terms
- eCTD (Electronic Common Technical Document) — the five-module submission format in which CMC data is filed as Module 3.
- Investigational New Drug (IND) — the application type for which an initial, tiered CMC package is first required.
- FDA Process Validation — the CGMP lifecycle framework underlying the manufacturing-controls component of CMC.
- ICH Q7 (GMP for Active Pharmaceutical Ingredients) — the harmonized API manufacturing-quality standard CMC quality sections reference.
- Complete Response Letter (CRL) — one regulatory consequence of an inadequate CMC package at the marketing-application stage.
Frequently Asked Questions
What does CMC stand for in the pharmaceutical industry?
CMC stands for Chemistry, Manufacturing, and Controls. It is the standard shorthand for the body of data describing what a drug substance or drug product is and how it is consistently made and controlled to meet that description, distinct from the nonclinical data on how a product behaves in animals or the clinical data on how it behaves in people.
What is included in a CMC package?
A CMC package is built to address five core questions at a depth appropriate to the product’s development stage: identity (chemical structure and synthesis route, or expression system and molecular characterization for a biologic), strength (confirmation that each batch contains the labeled amount of active ingredient), quality and purity (specifications and analytical test methods), manufacturing process (including in-process controls), and stability (data supporting the proposed container closure system and shelf life).
Where is CMC information filed in a regulatory submission?
In an eCTD-formatted application to FDA or another ICH-aligned regulator, CMC information is filed as Module 3 (Quality), organized by the ICH Common Technical Document structure into drug-substance and drug-product sections covering manufacture, characterization, control, and stability. Module 2 includes a Quality Overall Summary that synthesizes the Module 3 data for reviewers.
Does the CMC package required for an IND differ from what’s needed for a marketing application?
Yes. FDA and other ICH-aligned regulators apply a tiered, risk-based standard: a CMC package sufficient to support first-in-human dosing under an Investigational New Drug (IND) application is deliberately less exhaustive than the CMC package required to support a marketing application, where manufacturing-process validation, continued process verification, tightened specifications based on accumulated batch history, and more extensive characterization are expected.
What happens if a CMC package is incomplete or unconvincing?
An incomplete or unconvincing CMC package is one of the most common substantive grounds for regulatory delay. FDA can place a clinical hold on an IND, or issue a Complete Response Letter (CRL) on a marketing application, specifically because the submitted CMC data does not adequately establish identity, strength, quality, purity, or manufacturing consistency — independent of whether the nonclinical and clinical data packages are sound.
Is CMC the same thing as GMP?
No. CMC is the product-specific data package on identity, manufacturing, and controls submitted as part of a regulatory application, while GMP (Good Manufacturing Practice) is the manufacturing-quality framework that operations are expected to comply with — for example, ICH Q7 for active pharmaceutical ingredient manufacturing. FDA Process Validation, the CGMP lifecycle approach to demonstrating manufacturing consistency, is one of the frameworks the “controls” component of CMC draws on.
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="Chemistry, Manufacturing, and Controls (CMC)"
vocab-term-identifier="https://casrai.org/dictionary/term/chemistry-manufacturing-and-controls-cmc" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/chemistry-manufacturing-and-controls-cmc",
"name": "Chemistry, Manufacturing, and Controls (CMC)",
"identifier": "https://casrai.org/dictionary/term/chemistry-manufacturing-and-controls-cmc",
"description": "A regulatory submission qualifies as containing CMC information when it documents, for a specific drug substance and/or drug product, the identity, composition, and manufacturing process used to produce it; the in-process controls and specifications (analytical test methods and acceptance criteria) used to confirm its strength, quality, and purity at each stage; and the stability data supporting the proposed container closure system and shelf life. In an eCTD-formatted submission to FDA or another ICH-aligned regulator, this material is filed as Module 3 (Quality) -- CMC is the informal, universally-used shorthand for that module's content, not a separate submission or a formal ICH-defined term itself. A document that describes only the clinical protocol, nonclinical toxicology, or regulatory administrative forms, with no data on how the product is made, tested, or controlled, does not constitute CMC information regardless of how complete it is on those other dimensions.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/clinical-research#set",
"url": "https://casrai.org/dictionary/term/chemistry-manufacturing-and-controls-cmc",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-08-15T04:34:32",
"inLanguage": "en"
}
